Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

Partnerships

At Exosome Diagnostics, collaboration is a key focus of both our business and our culture. We are establishing partnerships with industry, academia, advocacy, and governmental organizations to help advance the application and potential of our exosome-based technology.

Find out more about our collaborations with:

The Most Comprehensive Biofluid-Based Molecular Analysis Platform
A variety of companies and organizations choose to work with Exosome Diagnostics because our platform enables:

  • Efficient isolation of RNA from exosomes
  • Molecular testing across a range of disease areas
  • Biomarker discovery and the development of companion diagnostics

For maximum mutation detection, we offer the only single-capture exosomal RNA and cell-free DNA (cfDNA) combined extraction from the same sample, allowing for the greatest total yield of nucleic acids for rare mutation detection. This presents a distinct advantage, as solely utilizing a cfDNA platform cannot enable the capture or analysis of critical exosomal RNA.

Top-Line Comparison Exosomes cfDNA CTC
Exosome Diagnostics’ Platform Offers More Comprehensive Molecular Analysis than CTCs and cfDNA
Analysis Capability
Combines the mutation analysis power of RNA, DNA and cfDNA for increased sensitivity Yes No No
Analysis of RNA transcription profiles (mRNA, splice variants, miRNA, IncRNA, etc.) Yes No Yes*
Detects systemic changes to disease Yes No No
Analysis of RNA/DNA/protein profiles from tumor cells that are still alive inside the solid tumor Yes No** No***
Protein status Yes No Yes
Clinical Utility
Real-time snapshot of events in the tumor Yes Yes Yes
Simple workflow of sample acquisition and processing Yes Yes No
Fresh or frozen biobanked material Yes Yes No
Broad applicability beyond oncology Yes No No

* Only some CTC platforms
** cfDNA is only released from dying cells
*** Most CTCs will never metastisize, unclear how the transcriptome status compares to cells within the tumor

cfDNA: Cell-Free or Circulating-Free Diagnostics
CTCs: Circulating Tumor Cells